Developer docs
API playgroundTry for free, no card

Search company profiles

Weave

Full company profile

uuid0000exn

Namestring
Weave
Legal namestring
Weave Bio
Websiteurl
weave.bio
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Weave Bio operates an AI-native regulatory automation platform that helps pharmaceutical, biotechnology, and contract research organizations prepare, manage, and submit regulatory dossiers across the drug development lifecycle. Founded in 2022 and headquartered in San Francisco, the company targets regulatory teams handling IND, NDA, BLA, and CTA submissions to the FDA, EMA, and other global health authorities, replacing fragmented, document-heavy manual workflows with an integrated workspace spanning authoring, source-data extraction, review, eCTD assembly, publishing, and post-submission Health Authority Question (HAQ) response management.

The product surface comprises three interconnected modules: the core Weave Platform as the central authoring and dossier workspace, the eCTD Submission Builder for end-to-end submission preparation, and HAQ Manager for post-submission HAQ response. The platform is built on AWS infrastructure using OpenAI GPT-4.1 and text-embedding-3-small under Zero Data Retention agreements, with proprietary orchestration layers that provide AI-driven drafting, semantic search across source files, sentence-level traceability from source data to dossier, anomaly detection for inconsistencies, customizable AutoReview, and bidirectional sync with Veeva Vault. Technical validation includes a published joint study with Takeda reporting approximately 97% reduction in first-drafting time for IND nonclinical written summaries with no critical AI-generated regulatory errors identified in independent QC, and HAQ Manager reporting 100% precision at 99.7% recall on FDA/EMA question files.

The company operates a quote-based SaaS model with multi-year enterprise contracts and does not publicly disclose pricing. Distribution combines direct enterprise field sales from San Francisco with an exclusive CRO design partnership with Parexel (which gains sole CRO rights to Weave's solutions post-launch) and a technology partnership with Syner-G, which embeds Weave inside its 3D Intelligence (3Di) service offering. Weave Bio has raised approximately $43 million across multiple funding rounds, including a $20 million Series A led by USVP in October 2025, and reports an 11–50 employee headcount range. Named customers include Takeda, Argenx, Recursion, Shattuck Labs, Vistagen, Trace Biosciences, Faeth Therapeutics, Parexel, and Syner-G, spanning enterprise pharma, biotech startups, and CROs.

Short descriptiontext

Weave Bio provides an AI-native regulatory automation platform that helps pharmaceutical, biotechnology, and CRO companies prepare, manage, and submit IND, NDA, and CTA dossiers to global health authorities with full traceability from source data to submission.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulatory affairs software, AI regulatory submissions, eCTD submission builder, IND NDA automation, pharma compliance platform
Industry2 codes
PRIMARYHLAGAJAL
Regulatory Information Management (RIM) & Submission Publishing Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Regulatory Affairs Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Licensing
TypeSubscription Recurring
Description

Weave Bio operates as a SaaS platform providing AI-native regulatory automation to pharma, biotech, and CRO companies. The platform is offered through subscription/licensing arrangements, likely tiered by team size or program scope, with organizations licensing access to the platform for regulatory workflow management. No specific pricing tiers are publicly disclosed.

weave.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1No publicly listed pricing tiers available.
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Contact sales / Request a demo is the primary engagement method observed across all product pages.

weave.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1AutoIND
Description

AI-powered platform designed to streamline regulatory document drafting, reviewing, and submitting for IND applications in drug development. Capable of producing first draft in a single day.

vcaonline.com
+4 more records
Core offering1 text field

Weave Bio provides an AI-native regulatory automation SaaS platform that supports the entire regulatory content lifecycle for pharmaceutical and biotech companies—from Pre-IND through NDA and post-market. Its platform combines an AI-powered document editor, a smart Data Room for source data, a Dossier Manager, an eCTD Submission Builder, and an HAQ Manager module to enable drafting, reviewing, publishing, and responding to Health Authority Questions with built-in FDA, EMA, and global regulatory compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • ~97% reduction in first-drafting time for IND nonclinical written summaries (from ~100 hours to 2.6–3.7 hours)
+7 more records
Product overview1 text field

Weave Bio offers an AI-native regulatory platform comprising three interconnected products: the core Weave Platform as the central workspace for document management, the eCTD Submission Builder module for end-to-end regulatory submission preparation, and the HAQ Manager module for post-submission Health Authority Question response management. The AutoIND feature specifically accelerates IND drafting. All products share a common data backbone connecting source files to dossier content, enabling traceability and content reuse across the regulatory lifecycle from Pre-IND through post-market.

Product and service6 records
1Weave Platform
CategoryRegulatory Affairs Software
Description

AI-native regulatory platform that supports the entire regulatory content lifecycle from authoring to publishing and response management. Provides a connected workspace with Document Editor, Data Room, and Dossier Manager components for managing complex dossiers across the therapeutic lifecycle. Target users are regulatory affairs, medical writing, and regulatory operations teams at pharma, biotech, and CROs.

2eCTD Submission Builder
CategoryRegulatory Submission Software
Description

AI-powered module for drafting, assembling, reviewing, verifying, and publishing eCTD regulatory submissions. Supports Modules 1-5 and enables movement from raw data to submission-ready packages with ~97% time reduction to first draft. Target users are regulatory operations and regulatory submissions teams at pharma, biotech, and CROs.

3HAQ Manager
CategoryRegulatory Response Management Software
Description

AI-based tool for managing Health Authority Questions during regulatory review. Extracts questions with 100% precision at 99.7% recall, identifies relevant source files, populates metadata, and generates draft responses in minutes. Saves 500-3,500 hours per year per application. Target users are regulatory affairs teams responding to FDA and EMA inquiries.

4AutoIND
CategoryRegulatory Submission Software
Description

AI-powered offering specifically designed for IND (Investigational New Drug) submissions. Produces first draft in a single day, reducing the traditional IND submission process from over a year to a day. Target users are biotech companies preparing their first INDs and regulatory affairs teams managing IND-stage programs.

5NDA Workflow
CategoryRegulatory Submission Software
Description

AI-native workflow for New Drug Application submissions developed in partnership with Parexel. Supports full NDA submissions with AI for data extraction, content verification, and automated authoring, enabling 60% faster authoring timelines than traditional manual methods. Includes a pre-loaded Baseline NDA template set available in every account. Target users are regulatory affairs and medical writing teams at pharma and biotech companies managing NDA-stage programs.

6Global Submissions
CategoryRegulatory Submission Software
Description

Expanded platform support for global regulatory submissions with customizable dossier structures for different health authorities. Includes a preloaded EU Clinical Trial Application (CTA) template built to EMA section hierarchies and custom template builder for additional markets. Target users are regulatory affairs teams coordinating submissions across FDA, EMA, and other global health authorities.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-01
Description

Syner-G partnered with Weave Bio as its technology provider for AI-augmented authoring and knowledge management across the IND-to-NDA lifecycle. Syner-G launched its 3D Intelligence (3Di) enterprise AI transformation service for biopharma, piloted since October 2025, using Weave Bio's platform for regulatory authoring. The service has yielded significant reductions in authoring time without compromising quality.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

Parexel, a global clinical research organization, entered a strategic partnership with Weave Bio in September 2025 to accelerate regulatory submission processes. Parexel serves as Weave's CRO design partner, gaining exclusivity as the only CRO licensed to use Weave's solutions after new product launches. The collaboration leverages Weave's AI technology with Parexel's regulatory expertise to support faster IND and NDA applications. Parexel has demonstrated 50% faster completion of IND applications using Weave's AutoIND platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Weave Bio formed its inaugural Strategic Advisory Board in March 2026, bringing together senior executives from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford University. The board provides strategic guidance on regulatory science, health authority policy, and AI integration to shape the evolution of Weave's platform and advance responsible AI adoption in life sciences regulatory workflows.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant life sciences cloud platform with Veeva Vault RIM, submissions, and quality suite. Weave positions as the AI-native authoring layer that integrates with Veeva, but Veeva's incumbent footprint across pharma R&D makes it the most strategically important peer for distribution and competitive overlap.

TypeDirect peer
Description

LifeSphere Regulatory and safety suite used by mid-to-large pharma for RIM, IDMP, and submission management. Most direct functional competitor to Weave's eCTD submission and dossier management capabilities, with growing investment in AI authoring features.

TypeDirect peer
Description

Specialist in regulatory submission publishing (docuBridge, eCTDplus) serving pharma regulatory teams. Directly comparable in the eCTD submission publishing and lifecycle management workflow that Weave's Submission Builder targets.

TypeDirect peer
Description

AI-driven life sciences services and technology firm with regulatory, medical, and commercial offerings; cited in Weave's own data via the 2022 HAQ Manager time-savings survey. Overlaps with Weave in regulatory authoring, content automation, and pharma commercialization AI.

TypeDirect peer
Description

Enterprise NLG platform widely deployed in pharma regulatory and medical writing automation (e.g., at Sanofi). Direct competitor for AI-authored regulatory narratives and structured reporting, the same core capability Weave markets for IND/NDA authoring.

TypeBroad incumbent
Description

Global CRO and life sciences technology provider with regulatory services and proprietary assets like Linguamatics NLP for biomedical text. Competes with Weave on enterprise pharma regulatory offerings while also providing potential partnership lanes.

TypeOthers
Description

Global CRO and Weave's exclusive design partner for AI-augmented regulatory services. Functions simultaneously as a customer, channel partner, and indirect competitor for outsourced regulatory writing services that Weave's automation may substitute.

TypeDirect peer
Description

Life sciences AI platform focused on clinical development, data automation, and submission acceleration. Comparable as a domain-specialized AI vendor selling into pharma R&D with similar GTM benchmarks and target buyer.

TypeBroad incumbent
Description

Large global CRO with growing technology-enabled regulatory and submission services. Competes for the same enterprise pharma and biotech procurement budgets and increasingly integrates AI into its regulatory service offerings.

TypeEmerging player
Description

Niche player in regulatory information management and submission planning acquired by LORENZ; competes in the RIM adjacent space where Weave is expanding. Smaller scale but focused overlap with Weave's autoIND / dossier coordination capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Weave

Regulatory Affairs Softwareweave.bio

Weave Bio provides an AI-native regulatory automation platform that helps pharmaceutical, biotechnology, and CRO companies prepare, manage, and submit IND, NDA, and CTA dossiers to global health authorities with full traceability from source data to submission.

What Weave does

Weave Bio operates an AI-native regulatory automation platform that helps pharmaceutical, biotechnology, and contract research organizations prepare, manage, and submit regulatory dossiers across the drug development lifecycle. Founded in 2022 and headquartered in San Francisco, the company targets regulatory teams handling IND, NDA, BLA, and CTA submissions to the FDA, EMA, and other global health authorities, replacing fragmented, document-heavy manual workflows with an integrated workspace spanning authoring, source-data extraction, review, eCTD assembly, publishing, and post-submission Health Authority Question (HAQ) response management.

The product surface comprises three interconnected modules: the core Weave Platform as the central authoring and dossier workspace, the eCTD Submission Builder for end-to-end submission preparation, and HAQ Manager for post-submission HAQ response. The platform is built on AWS infrastructure using OpenAI GPT-4.1 and text-embedding-3-small under Zero Data Retention agreements, with proprietary orchestration layers that provide AI-driven drafting, semantic search across source files, sentence-level traceability from source data to dossier, anomaly detection for inconsistencies, customizable AutoReview, and bidirectional sync with Veeva Vault. Technical validation includes a published joint study with Takeda reporting approximately 97% reduction in first-drafting time for IND nonclinical written summaries with no critical AI-generated regulatory errors identified in independent QC, and HAQ Manager reporting 100% precision at 99.7% recall on FDA/EMA question files.

The company operates a quote-based SaaS model with multi-year enterprise contracts and does not publicly disclose pricing. Distribution combines direct enterprise field sales from San Francisco with an exclusive CRO design partnership with Parexel (which gains sole CRO rights to Weave's solutions post-launch) and a technology partnership with Syner-G, which embeds Weave inside its 3D Intelligence (3Di) service offering. Weave Bio has raised approximately $43 million across multiple funding rounds, including a $20 million Series A led by USVP in October 2025, and reports an 11–50 employee headcount range. Named customers include Takeda, Argenx, Recursion, Shattuck Labs, Vistagen, Trace Biosciences, Faeth Therapeutics, Parexel, and Syner-G, spanning enterprise pharma, biotech startups, and CROs.

Weave firmographics

Firmographics
Name
Weave
Legal name
Weave Bio
Website
https://weave.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Weave Bio provides an AI-native regulatory automation platform that helps pharmaceutical, biotechnology, and CRO companies prepare, manage, and submit IND, NDA, and CTA dossiers to global health authorities with full traceability from source data to submission.
Ownership category
akta.pro rank

Weave industry classification

Industry
Product category
Regulatory Affairs Software
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAL
Regulatory Information Management (RIM) & Submission Publishing Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Regulatory affairs software
  • AI regulatory submissions
  • ECTD submission builder
  • IND NDA automation
  • Pharma compliance platform

Where Weave is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Weave business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. SaaS Platform Licensing: Weave Bio operates as a SaaS platform providing AI-native regulatory automation to pharma, biotech, and CRO companies. The platform is offered through subscription/licensing arrangements, likely tiered by team size or program scope, with organizations licensing access to the platform for regulatory workflow management. No specific pricing tiers are publicly disclosed.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractNo publicly listed pricing tiers available.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Weave product offering

Product offering

Core offering

Weave Bio provides an AI-native regulatory automation SaaS platform that supports the entire regulatory content lifecycle for pharmaceutical and biotech companies—from Pre-IND through NDA and post-market. Its platform combines an AI-powered document editor, a smart Data Room for source data, a Dossier Manager, an eCTD Submission Builder, and an HAQ Manager module to enable drafting, reviewing, publishing, and responding to Health Authority Questions with built-in FDA, EMA, and global regulatory compliance.

Product overview

Weave Bio offers an AI-native regulatory platform comprising three interconnected products: the core Weave Platform as the central workspace for document management, the eCTD Submission Builder module for end-to-end regulatory submission preparation, and the HAQ Manager module for post-submission Health Authority Question response management. The AutoIND feature specifically accelerates IND drafting. All products share a common data backbone connecting source files to dossier content, enabling traceability and content reuse across the regulatory lifecycle from Pre-IND through post-market.

Differentiator

Problem solved

Functional benefit

Brands

  • AutoIND: AI-powered platform designed to streamline regulatory document drafting, reviewing, and submitting for IND applications in drug development. Capable of producing first draft in a single day.
  • HAQ Manager
  • Submission Builder
  • eCTD Submission Builder
  • Weave

Products and services

  • Weave Platform AI-native regulatory platform that supports the entire regulatory content lifecycle from authoring to publishing and response management. Provides a connected workspace with Document Editor, Data Room, and Dossier Manager components for managing complex dossiers across the therapeutic lifecycle. Target users are regulatory affairs, medical writing, and regulatory operations teams at pharma, biotech, and CROs.
  • eCTD Submission Builder AI-powered module for drafting, assembling, reviewing, verifying, and publishing eCTD regulatory submissions. Supports Modules 1-5 and enables movement from raw data to submission-ready packages with ~97% time reduction to first draft. Target users are regulatory operations and regulatory submissions teams at pharma, biotech, and CROs.
  • HAQ Manager AI-based tool for managing Health Authority Questions during regulatory review. Extracts questions with 100% precision at 99.7% recall, identifies relevant source files, populates metadata, and generates draft responses in minutes. Saves 500-3,500 hours per year per application. Target users are regulatory affairs teams responding to FDA and EMA inquiries.
  • AutoIND AI-powered offering specifically designed for IND (Investigational New Drug) submissions. Produces first draft in a single day, reducing the traditional IND submission process from over a year to a day. Target users are biotech companies preparing their first INDs and regulatory affairs teams managing IND-stage programs.
  • NDA Workflow AI-native workflow for New Drug Application submissions developed in partnership with Parexel. Supports full NDA submissions with AI for data extraction, content verification, and automated authoring, enabling 60% faster authoring timelines than traditional manual methods. Includes a pre-loaded Baseline NDA template set available in every account. Target users are regulatory affairs and medical writing teams at pharma and biotech companies managing NDA-stage programs.
  • Global Submissions Expanded platform support for global regulatory submissions with customizable dossier structures for different health authorities. Includes a preloaded EU Clinical Trial Application (CTA) template built to EMA section hierarchies and custom template builder for additional markets. Target users are regulatory affairs teams coordinating submissions across FDA, EMA, and other global health authorities.

Quantifiable outcome

  • ~97% reduction in first-drafting time for IND nonclinical written summaries (from ~100 hours to 2.6–3.7 hours)
  • +7 more outcomes

Companies that use Weave

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Weave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature11 records

Weave partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Syner-GcoreTechnology or Integration · 1 October 2025Syner-G partnered with Weave Bio as its technology provider for AI-augmented authoring and knowledge management across the IND-to-NDA lifecycle. Syner-G launched its 3D Intelligence (3Di) enterprise AI transformation service for biopharma, piloted since October 2025, using Weave Bio's platform for regulatory authoring. The service has yielded significant reductions in authoring time without compromising quality.
  • ParexelcoreStrategic or Co-development Partner · 30 September 2025Parexel, a global clinical research organization, entered a strategic partnership with Weave Bio in September 2025 to accelerate regulatory submission processes. Parexel serves as Weave's CRO design partner, gaining exclusivity as the only CRO licensed to use Weave's solutions after new product launches. The collaboration leverages Weave's AI technology with Parexel's regulatory expertise to support faster IND and NDA applications. Parexel has demonstrated 50% faster completion of IND applications using Weave's AutoIND platform.
  • Strategic Advisory Board (Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, Stanford University)minorStrategic or Co-development PartnerWeave Bio formed its inaugural Strategic Advisory Board in March 2026, bringing together senior executives from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford University. The board provides strategic guidance on regulatory science, health authority policy, and AI integration to shape the evolution of Weave's platform and advance responsible AI adoption in life sciences regulatory workflows.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Weave competitors and assessment

Company assessment

Broad incumbents

  • Veeva Systems: Dominant life sciences cloud platform with Veeva Vault RIM, submissions, and quality suite. Weave positions as the AI-native authoring layer that integrates with Veeva, but Veeva's incumbent footprint across pharma R&D makes it the most strategically important peer for distribution and competitive overlap.
  • IQVIA: Global CRO and life sciences technology provider with regulatory services and proprietary assets like Linguamatics NLP for biomedical text. Competes with Weave on enterprise pharma regulatory offerings while also providing potential partnership lanes.
  • ICON plc: Large global CRO with growing technology-enabled regulatory and submission services. Competes for the same enterprise pharma and biotech procurement budgets and increasingly integrates AI into its regulatory service offerings.

Direct peers

  • ArisGlobal: LifeSphere Regulatory and safety suite used by mid-to-large pharma for RIM, IDMP, and submission management. Most direct functional competitor to Weave's eCTD submission and dossier management capabilities, with growing investment in AI authoring features.
  • LORENZ Life Sciences: Specialist in regulatory submission publishing (docuBridge, eCTDplus) serving pharma regulatory teams. Directly comparable in the eCTD submission publishing and lifecycle management workflow that Weave's Submission Builder targets.
  • Indegene: AI-driven life sciences services and technology firm with regulatory, medical, and commercial offerings; cited in Weave's own data via the 2022 HAQ Manager time-savings survey. Overlaps with Weave in regulatory authoring, content automation, and pharma commercialization AI.
  • Yseop: Enterprise NLG platform widely deployed in pharma regulatory and medical writing automation (e.g., at Sanofi). Direct competitor for AI-authored regulatory narratives and structured reporting, the same core capability Weave markets for IND/NDA authoring.
  • Saama Technologies: Life sciences AI platform focused on clinical development, data automation, and submission acceleration. Comparable as a domain-specialized AI vendor selling into pharma R&D with similar GTM benchmarks and target buyer.

Others

  • Parexel: Global CRO and Weave's exclusive design partner for AI-augmented regulatory services. Functions simultaneously as a customer, channel partner, and indirect competitor for outsourced regulatory writing services that Weave's automation may substitute.

Emerging players

  • Cube RM: Niche player in regulatory information management and submission planning acquired by LORENZ; competes in the RIM adjacent space where Weave is expanding. Smaller scale but focused overlap with Weave's autoIND / dossier coordination capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Weave social profiles

Digital presence

Weave compliance and trust

Trust signal

Compliance2 records

Weave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Weave leadership team

Management profile

Number of profiles

Profiles3 records

Weave funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Weave M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weave

What does Weave do?

Weave Bio provides an AI-native regulatory automation SaaS platform that supports the entire regulatory content lifecycle for pharmaceutical and biotech companies—from Pre-IND through NDA and post-market. Its platform combines an AI-powered document editor, a smart Data Room for source data, a Dossier Manager, an eCTD Submission Builder, and an HAQ Manager module to enable drafting, reviewing, publishing, and responding to Health Authority Questions with built-in FDA, EMA, and global regulatory compliance.

Is Weave a public or private company?

Weave is a private company. It is classified as venture growth investor backed and is currently operating.

When was Weave founded?

Weave was founded in 2022. It employs 11 to 50 people.

Where is Weave based?

Weave is headquartered in San Francisco, United States, in the North America region.

How does Weave make money?

One revenue line is on record: saaS Platform Licensing.

Who are Weave's main competitors?

Broad incumbents on record are Veeva Systems, IQVIA and ICON plc. Direct peers are ArisGlobal, LORENZ Life Sciences, Indegene, Yseop and Saama Technologies. Parexel is listed as an others. Cube RM is listed as an emerging player.

Does Weave have an API?

No public API is recorded for Weave.

What industry is Weave in?

Weave's product category is Regulatory Affairs Software. Its primary akta.pro industry code is HLAGAJAL, Regulatory Information Management (RIM) & Submission Publishing Software, with a secondary code of HLAGAJAN, Knowledge Management & Scientific Collaboration / Literature Intelligence. Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyAnnovis turns to AI to fast-track its Alzheimer’s filingAnnovis Bio partnered with Weave Bio to use AI for drafting its FDA NDA for buntanetap, an oral therapy for Alzheimer's and Parkinson's. The company expects top-line Phase 3 data in March 2027 and aims to finish most of the NDA before then. Weave Bio's role is drafting, with Annovis retaining full regulatory responsibility.Longevity.TechnologyAnnovis taps Weave Bio’s AI to speed FDA submission for Alzheimer’s drugAnnovis partnered with Weave Bio to use AI for drafting and reviewing NDA documents for buntanetap, an Alzheimer's drug. The collaboration follows completion of a Phase 3 study enrolling 862 patients, exceeding the target of 760. Annovis plans database lock in December 2026 and a top-line data announcement in March 2027.FinancialContent Business PageBioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Collaborates With Weave Bio to Support Buntanetap NDA PreparationAnnovis Bio announced a collaboration with Weave Bio to support preparation of the NDA for buntanetap, its oral therapy for Alzheimer's and Parkinson's disease. The company's Phase 3 study enrolled 862 patients, exceeding the target of 760, and aims to lock the database in December 2026 with top-line data in March 2027.Investing.comAnnovis Bio partners with Weave Bio for NDA preparation By Investing.comAnnovis Bio partnered with Weave Bio to use AI for drafting and reviewing NDA documents for buntanetap, an Alzheimer's and Parkinson's therapy. The company completed enrollment in its Phase 3 trial with 862 patients, exceeding the target of 760, and expects top-line data in March 2027.Stock TitanAnnovis Bio, Weave Bio partner on planned buntanetap NDAAnnovis Bio announced a partnership with Weave Bio to use AI for drafting and managing the NDA for buntanetap, with the company's regulatory team retaining full responsibility. The pivotal Phase 3 Alzheimer's trial enrolled 862 patients, exceeding the target of 760, and aims for a top-line data readout in March 2027.SynBioBetaWeave Bio Partners with Takeda to Innovate AI-Driven Regulatory AutomationWeave Bio and Takeda announced a collaboration to deploy AI-native regulatory automation across 14 active programs. The partnership achieved a 97% reduction in time to first draft for IND submissions and a 68% average AI answer quality score. The companies align with FDA and EMA AI guidance emphasizing human oversight.pharmaphorumBoehringer signs AI drug discovery deal with OwkinBoehringer Ingelheim signed an agreement to deploy Owkin's K Pro AI platform in its oncology and immunology R&D, following a pilot that analyzed the $50 million MOSAIC dataset. Financial terms were not disclosed, and Owkin expects additional partnerships soon.Pharmaceutical TechnologyTakeda, Weave Bio collaborate on AI-driven automation in drug developmentTakeda and Weave Bio are collaborating to deploy Weave's AI regulatory automation platform across 14 drug development programs. The partnership reduced initial submission drafting time by 97% (from 100 to 3 hours) and achieved a 68% average AI answer quality score. Both companies state their approach aligns with FDA and EMA AI guidance.YahooWeave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development ActivitiesWeave Bio and Takeda announced a collaboration to deploy AI-native regulatory automation across 14 active drug development programs. The partnership reported a 97% reduction in time to first draft for IND submissions and a 68% average AI answer quality score. The companies aligned with FDA and EMA guidance on responsible AI use.Business Wire BlogWeave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development ActivitiesWeave Bio and Takeda announced a collaboration to deploy AI-native regulatory automation across 14 active drug development programs. A co-authored study showed a 97% reduction in time to first draft for IND submissions, from about 100 hours to three, with 95% faithfulness to source data.